High-dose methotrexate: The rationale...

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 3, 2009, Pages 224-225

  Cheok, Meyling H ^a   Evans, William E ^b   Kager, Leo ^c  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LETTER; OSTEOSARCOMA; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; BONE TUMOR; CHILD; DOSE RESPONSE; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHOTREXATE; OSTEOSARCOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 65449152213     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318196a2a6     Document Type: Letter

References (11)

1. Kamen BA. High-dose methotrexate: insecure rationale: take 2. J Pediatr Hematol Oncol. 2008;30:639-640.
2. Blay JY. Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle. Onkologie. 2007;30: 226-227.
3. Tunn PU, Reichardt P. Chemotherapy for osteosarcoma without high-dose metho-trexate: a 12-year follow-up on 53 patients. Onkologie. 2007;30:228-232.
4. Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: let the questions surcease - time for final acceptance. J Clin Oncol. 2008;26:4365-4366.
5. Sorich MJ, Pottier N, Pei D, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008;5:e83.
6. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polygluta-mates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest. 1996;97:73-80.
7. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate- polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994;94:1996-2001.
8. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986;314:471-477.
9. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505. 10. Cohen IJ. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol. 2004;26:156-163.
10. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacody-namics. J Clin Invest. 2005;115:110-117.
11. Whitehead VM, Shuster JJ, Vuchich MJ, et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2005;19:533-536. 13. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21: 1798-1809.